Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-975: Pembrolizumab with definitive chemoradiotherapy for esophageal carcinoma
jRCT2080225165Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC), esophagogastric junction cancer, esophageal adenocarcinoma (EAC) and 1 more comparing Pembrolizumab + dCRT with Placebo + dCRT (2 arms). Started Apr 2020; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophagogastric junction canceresophageal adenocarcinoma (EAC)esophageal cancer
Beyond the preview
Go deeper on jRCT2080225165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225165.